Combination of mTOR and EGFR targeting in an orthotopic xenograft model of head and neck cancer

Phase II trial of everolimus and erlotinib in patients with platinum-resistant recurrent and/or metastatic head and neck squamous cell carcinoma

(2015) E. Massarelli et al.   ANNALS OF ONCOLOGY

Rapamycin Impairs Antitumor CD8+ T-cell Responses and Vaccine-Induced Tumor Eradication

(2015) N. Chaoul et al.   CANCER RESEARCH

The relevance of ADCC for EGFR targeting: A review of the literature and a clinically-applicable method of assessment in patients

(2015) Martino Monteverde et al.   CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY

Comprehensive genomic characterization of head and neck squamous cell carcinomas

(2015)   NATURE

Targeting TORC1/2 Enhances Sensitivity to EGFR Inhibitors in Head and Neck Cancer Preclinical Models

(2015) Andre Cassell et al.   NEOPLASIA

The dual PI3K/mTOR inhibitor PKI-587 enhances sensitivity to cetuximab in EGFR-resistant human head and neck cancer models

(2014) V D'Amato et al.   BRITISH JOURNAL OF CANCER

Phase 1 and pharmacokinetic study of everolimus in combination with cetuximab and carboplatin for recurrent/metastatic squamous cell carcinoma of the head and neck

(2014) Nabil F. Saba et al.   CANCER

mTOR Co-Targeting in Cetuximab Resistance in Head and Neck Cancers Harboring PIK3CA and RAS Mutations

(2014) Zhiyong Wang et al.   JNCI-Journal of the National Cancer Institute

Frequent Mutation of the PI3K Pathway in Head and Neck Cancer Defines Predictive Biomarkers

(2013) V. W. Y. Lui et al.   Cancer Discovery

New promising molecular targets in head and neck squamous cell carcinoma

(2012) Julie E. Bauman et al.   CURRENT OPINION IN ONCOLOGY

Treatment options for patients with recurrent or metastatic squamous cell carcinoma of the head and neck, who progress after platinum-based chemotherapy

(2012) Diocésio A.P. de Andrade et al.   CURRENT OPINION IN ONCOLOGY

Decreased Lymphangiogenesis and Lymph Node Metastasis by mTOR Inhibition in Head and Neck Cancer

(2011) V. Patel et al.   CANCER RESEARCH

Molecular-targeted therapy of head and neck squamous cell carcinoma: beyond cetuximab-based therapy

(2011) Jean-Pascal Machiels et al.   CURRENT OPINION IN ONCOLOGY

Akt/mTOR Counteract the Antitumor Activities of Cixutumumab, an Anti-Insulin-like Growth Factor I Receptor Monoclonal Antibody

(2011) D. H. Shin et al.   MOLECULAR CANCER THERAPEUTICS

The mTOR-targeting drug temsirolimus enhances the growth-inhibiting effects of the cetuximab–bevacizumab–irradiation combination on head and neck cancer xenografts

(2011) Alexandre Bozec et al.   ORAL ONCOLOGY

Antitumor activity of cetuximab associated with the taxotere–cisplatin–fluorouracil (TPF) combination on an orthotopic head and neck cancer model

(2011) Alexandre Bozec et al.   ORAL ONCOLOGY

Therapeutic targets in head and neck squamous cell carcinoma: Identification, evaluation, and clinical translation

(2011) Jason D. Howard et al.   ORAL ONCOLOGY

Combined effects of bevacizumab with erlotinib and irradiation: a preclinical study on a head and neck cancer orthotopic model

(2008) A Bozec et al.   BRITISH JOURNAL OF CANCER

Platinum-Based Chemotherapy plus Cetuximab in Head and Neck Cancer

(2008) Jan B. Vermorken et al.   NEW ENGLAND JOURNAL OF MEDICINE

Dysregulated molecular networks in head and neck carcinogenesis

(2008) Alfredo A. Molinolo et al.   ORAL ONCOLOGY